Clinical Trial Update: Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Reparixin added to standard care to limit disease progression in patients with COVID-19 and other community-acquired pneumonia was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infectious Pneumonia

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Infectious Pneumonia, Severe COVID-19 | Phase 3 | Status: TERMINATED | Results posted: 2026-02-24